# ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy

> **NCT03712293** · NA · COMPLETED · sponsor: **InSightec** · enrollment: 9 (actual)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DEVICE:** BBB Disruption with Chemotherapy Arm

## Key facts

- **NCT ID:** NCT03712293
- **Lead sponsor:** InSightec
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-08-28
- **Primary completion:** 2023-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-03-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03712293

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03712293, "ExAblate Blood-Brain Barrier Disruption for Glioblastoma in Patients Undergoing Standard Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03712293. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*